antineoplastic agents	classified by	ATC
ATC	contains	antineoplastic agents
antineoplastic agents	include	chemotherapy
chemotherapy	is a	treatment
chemotherapy	targets	cancer cells
cancer cells	exhibit	uncontrolled proliferation
uncontrolled proliferation	leads to	tumor growth
tumor growth	causes	metastasis
metastasis	increases	mortality risk
mortality risk	predicts	poor prognosis
poor prognosis	indicates	need for aggressive therapy
aggressive therapy	may involve	combination chemotherapy
combination chemotherapy	reduces	relapse rate
relapse rate	affects	readmission probability
readmission probability	informs	discharge planning
discharge planning	improves	patient outcomes
patient outcomes	measured by	survival rate
survival rate	depends on	treatment efficacy
treatment efficacy	measured by	response rate
response rate	correlates with	biomarker expression
biomarker expression	assessed by	immunohistochemistry
immunohistochemistry	detects	HER2
HER2	is a	receptor
receptor	targeted by	trastuzumab
trastuzumab	is a	monoclonal antibody
monoclonal antibody	classified as	targeted therapy
targeted therapy	reduces	side effect burden
side effect burden	improves	quality of life
quality of life	predicts	adherence
adherence	influences	treatment success
treatment success	measured by	progression-free survival
progression-free survival	depends on	drug potency
drug potency	linked to	pharmacokinetics
pharmacokinetics	described by	half-life
half-life	affects	dosing schedule
dosing schedule	impacts	toxicity profile
toxicity profile	includes	neutropenia
neutropenia	increases	infection risk
infection risk	raises	hospitalization rate
hospitalization rate	predicts	readmission risk
readmission risk	informs	resource allocation
resource allocation	optimizes	cost-effectiveness
cost-effectiveness	evaluated by	incremental cost‑effectiveness ratio
incremental cost‑effectiveness ratio	guides	reimbursement decisions
reimbursement decisions	influence	drug availability
drug availability	affects	treatment choice
treatment choice	guided by	clinical guidelines
clinical guidelines	based on	evidence hierarchy
evidence hierarchy	ranks	randomized controlled trials
randomized controlled trials	produce	hazard ratios
hazard ratios	estimate	relative risk
relative risk	used in	meta‑analysis
meta‑analysis	informs	systematic reviews
systematic reviews	summarize	drug efficacy
drug efficacy	compared across	drug classes
drug classes	include	alkylating agents
alkylating agents	act by	DNA cross‑linking
DNA cross‑linking	induces	apoptosis
apoptosis	reduces	tumor burden
tumor burden	measured by	imaging
imaging	utilizes	PET‑CT
PET‑CT	detects	metabolic activity
metabolic activity	indicates	residual disease
residual disease	predicts	recurrence
recurrence	increases	surveillance intensity
surveillance intensity	requires	follow‑up visits
follow‑up visits	improve	early detection
early detection	lowers	mortality
mortality	tracked by	cancer registry
cancer registry	provides	epidemiological data
epidemiological data	used for	population health
population health	informs	public health policy
public health policy	shapes	screening programs
screening programs	target	high‑risk groups
high‑risk groups	identified by	risk calculators
risk calculators	incorporate	genetic variants
genetic variants	discovered by	genome‑wide association studies
genome‑wide association studies	identify	susceptibility loci
susceptibility loci	linked to	drug response
drug response	predicts	pharmacogenomic profile
pharmacogenomic profile	guides	personalized medicine
personalized medicine	reduces	adverse events
adverse events	monitored by	adverse event reporting
adverse event reporting	feeds into	pharmacovigilance
pharmacovigilance	detects	safety signals
safety signals	trigger	label changes
label changes	affect	prescribing patterns
prescribing patterns	influence	drug utilization
drug utilization	measured by	prescription claims
prescription claims	analyzed for	adherence metrics
adherence metrics	correlate with	treatment outcomes
treatment outcomes	evaluated by	survival statistics
survival statistics	reported in	clinical trials
clinical trials	register	trial phases
trial phases	progress from	phase I to phase III
phase III	confirms	efficacy
efficacy	supports	regulatory approval
regulatory approval	grants	market access
market access	ensures	patient access
patient access	determines	health equity
